TLR4 and Hepatic fibrosis: Unpretreated MSC did not show clear improvement of hepatic fibrosis, and TLR4+IFN-γ-activated MSC alleviated liver pathology, without increase of mortality rate; however, TLR2+IFN-γ-activated MSC displayed aggravated immunopathology